kidney disease progression

肾脏疾病进展
  • 文章类型: Journal Article
    据报道,免疫球蛋白A肾病(IgAN)与乙型肝炎病毒(HBV)感染共存。尽管这种联系具有临床意义,缺乏全面的研究来调查HBV感染后各种常见病症的影响以及抗HBV治疗对IgAN进展的潜在影响.
    我们调查了3种不同的HBV感染状态,包括慢性HBV感染,解决HBV感染,以及乙型肝炎抗原在肾组织中的沉积,在1961年IgAN患者的随访数据库中。IgAN进展定义为估计的肾小球滤过率(eGFR)损失>40%。多变量原因特异性风险模型来分析HBV状态和IgAN进展之间的关系。
    慢性HBV感染被确定为IgAN进展的独立危险因素,由两个预匹配分析支持(危险比[HR],1.61;95%置信区间[CI],1.06-2.44;P=0.024)和倾向得分匹配分析(HR,1.74;95%CI1.28-2.37;P<0.001)。相反,已解决的HBV感染与IgAN进展无显着关联(HR,1.01;95%CI0.67-1.52;P=0.969)。此外,肾脏中HBV沉积的存在和抗HBV治疗的使用似乎不是肾脏结局的显著危险因素(P>0.05).
    慢性HBV感染是IgAN进展的独立危险因素,而解决HBV感染不是。在IgAN患者中,应加强对并发慢性HBV感染的管理。肾脏中HBV沉积的存在和抗HBV药物的使用不会影响并发HBV感染的IgAN患者的肾脏疾病进展。
    UNASSIGNED: Immunoglobulin A nephropathy (IgAN) has been reported to coexist with hepatitis B virus (HBV) infection. Despite the clinical significance of this association, there is a lack of comprehensive research investigating the impact of various common conditions following HBV infection and the potential influence of anti-HBV therapy on the progression of IgAN.
    UNASSIGNED: We investigated 3 distinct states of HBV infection, including chronic HBV infection, resolved HBV infection, and the deposition of hepatitis B antigens in renal tissue, in a follow-up database of 1961 patients with IgAN. IgAN progression was defined as a loss of estimated glomerular filtration rate (eGFR) >40%. Multivariable cause-specific hazards models to analyze the relationship between HBV states and IgAN progression.
    UNASSIGNED: Chronic HBV infection was identified as an independent risk factor for IgAN progression, supported by both prematching analysis (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.06-2.44; P = 0.024) and propensity-score matching analysis (HR, 1.74; 95% CI 1.28-2.37; P < 0.001). Conversely, resolved HBV infection showed no significant association with IgAN progression (HR, 1.01; 95% CI 0.67-1.52; P = 0.969). Moreover, the presence of HBV deposition in the kidneys and the utilization of anti-HBV therapy did not appear to be significant risk factors for renal outcomes (P > 0.05).
    UNASSIGNED: Chronic HBV infection is an independent risk factor for IgAN progression, whereas resolved HBV infection is not. In patients with IgAN, management of concurrent chronic HBV infection should be enhanced. The presence of HBV deposition in the kidneys and the use of anti-HBV medications do not impact the kidney disease progression in patients with IgAN with concurrent HBV infection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    UNASSIGNED: Acute kidney injury (AKI) affects up to 20% of hospitalizations and is associated with chronic kidney disease, cardiovascular disease, increased mortality, and increased health care costs. Proper documentation of AKI in discharge summaries is critical for optimal monitoring and treatment of these patients once discharged. Currently, there is limited literature evaluating the quality of discharge communication after AKI. This study aimed to evaluate the accuracy and quality of documentation of episodes of AKI at a tertiary care center in British Columbia, Canada.
    UNASSIGNED: This was a retrospective chart review study of adult patients who experienced AKI during hospital admission between January 1, 2018, and December 31, 2018. Laboratory data were used to identify all admissions to the cardiac and general medicine ward complicated by AKI defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria. A random sample of 300 AKI admissions stratified by AKI severity (eg, stages 1, 2, and 3) were identified for chart review. Patients were excluded if they required ongoing renal replacement therapy after admission, had a history of kidney transplant, died during their admission, or did not have a discharge summary available. Discharge summaries were reviewed for documentation of the following: presence of AKI, severity of AKI, AKI status at discharge, practitioner and laboratory follow-up plans, and medication changes.
    UNASSIGNED: A total of 1076 patients with 1237 AKI admissions were identified. Of the 300 patients selected for discharge summary review, 38 met exclusion criteria. In addition, AKI was documented in 140 (53%) discharge summaries and was more likely to be documented in more severe AKI: stage 1, 38%; stage 2, 51%; and stage 3, 75%. Of those with their AKI documented, 94 (67%) documented AKI severity, and 116 (83%) mentioned the AKI status or trajectory at the time of discharge. A total of 239 (91%) of discharge summaries mentioned a follow-up plan with a practitioner, but only 23 (10%) had documented follow-up with nephrology. Patients with their AKI documented were more likely to have nephrology follow-up than those without AKI documented (17% vs 1%). Regarding laboratory investigations, 92 (35%) of the summaries had documented recommendations. In summaries that included medications typically held during AKI, only about half made specific reference to those medications being held, adjusted, or documented a post-discharge plan for that medication. For those with nonsteroidal anti-inflammatory drugs (NSAIDs) listing, 64% of discharge summaries mentioned holding, and 9% mentioned a discharge plan. For those with angiotensin converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) listing, 38% mentioned holding these medications, and 46% mentioned a discharge plan. In summaries with diuretics listed, 35% mentioned holding, and 51% included a discharge plan.
    UNASSIGNED: We found suboptimal quality and completeness of discharge reporting in patients hospitalized with AKI. This may contribute to inadequate follow-up and post-hospitalization care for this patient population. Strategies are required for increasing the presence and quality of AKI reporting in discharge summaries. Limitations include our definition of AKI based on lab criteria, which may have missed some of the injuries that met the criteria based on urine output. Another limitation is that our definition of AKI based on the highest and lowest creatinine during admission may have led to some overclassification. In addition, without outpatient laboratories, it is possible that we have not captured the true baseline creatinine in some patients.
    UNASSIGNED: L’insuffisance rénale aiguë (IRA) complique jusqu’à 20 % des hospitalisations; elle est associée à l’insuffisance rénale chronique, aux maladies cardiovasculaires, à une mortalité accrue et à une augmentation des coûts de santé. La documentation appropriée de l’IRA dans les résumés de départ est essentielle pour optimiser la surveillance et le traitement des patients après leur sortie de l’hôpital. Il existe peu de littérature évaluant la qualité de la documentation de l’IRA dans les résumés de départ. Cette étude visait à évaluer l’exactitude et la qualité de la documentation des épisodes d’IRA dans un center de soins tertiaires de la Colombie-Britannique (Canada).
    UNASSIGNED: Il s’agit d’une étude rétrospective des dossiers de patients adultes ayant présenté une IRA au cours de leur admission à l’hôpital entre le 1er janvier 2018 et le 31 décembre 2018. Les données de laboratoire ont été utilisées pour répertorier toutes les admissions compliquées par une IRA (définie par les critères KDIGO) dans les services de cardiologie et de médecine générale. Un échantillon aléatoire de 300 admissions avec IRA stratifiée selon sa gravité (p. ex., stade, 1, 2 et 3) a été constitué pour l’examen des dossiers. Ont été exclus les patients qui avaient eu besoin d’une thérapie de suppléance rénale continue après leur admission, ceux qui avaient des antécédents de transplantation rénale, ceux qui étaient décédés pendant leur admission et ceux pour qui aucun résumé de départ n’était disponible. Les résumés de départ ont été examinés à la recherche d’une mention des éléments suivants : présence d’une IRA, gravité de l’IRA, statut de l’IRA à la sortie, plans de suivi pour les tests de laboratoire et suivi avec un praticien, changements dans la médication.
    UNASSIGNED: En tout, 1 076 patients avec un total de 1 237 admissions avec IRA ont été identifiés. Parmi les 300 patients sélectionnés pour l’examen du résumé de départ, 38 répondaient aux critères d’exclusion. L’IRA avait été documentée dans 140 (53 %) des cas et plus elle était grave, plus elle était susceptible d’être documentée (stade 1 = 38 %; stade 2 = 51 %; stade 3 = 75 %). Parmi ceux où l’IRA était documentée, 94 (67 %) mentionnaient sa gravité et 116 (83 %) mentionnaient son statut ou sa trajectoire à la sortie du patient. Un plan de suivi avec le praticien était mentionné dans 239 (91 %) des résumés de départ, mais seuls 23 (10 %) mentionnaient un suivi en néphrologie. Les patients dont l’IRA était documentée étaient plus susceptibles de faire l’objet d’un suivi en néphrologie que ceux sans mention de l’IRA (17 % contre 1 %). En ce qui concerne les plans de suivi de laboratoire, 92 (35 %) des résumés contenaient des recommandations. Dans les résumés qui mentionnaient des médicaments normalement maintenus pendant un épisode d’IRA, seule la moitié environ faisait spécifiquement référence à ces médicaments comme ayant été cessés, ajustés ou documentés dans un plan post-sortie. Dans les résumés de départ qui listaient des AINS, 64 % mentionnaient qu’ils avaient été cessés temporairement et 9 % comprenaient un plan au congé de l’hôpital. Dans les résumés de départ qui listaient des IECA/ARA, 38 % mentionnaient que ces médicaments avaient été cessés temporairement et 46 % comprenaient un plan au congé de l’hôpital. Dans les résumés qui listaient des diurétiques, 35 % mentionnaient qu’ils avaient été cessés temporairement et 51 % comprenaient un plan au congé de l’hôpital.
    UNASSIGNED: Nous avons constaté que la qualité et l’exhaustivité des résumés de départ étaient sous-optimales chez les patients hospitalisés ayant vécu un épisode d’IRA. Cette situation peut contribuer à l’inadéquation du suivi et des soins post-hospitalization pour cette population de patients. Des stratégies sont nécessaires pour accroître la documentation d’un épisode d’IRA dans les résumés de départ et augmenter la qualité de sa communication. Les résultats de cette étude sont notamment limités par notre définition de l’IRA fondée sur des critères de laboratoire qui pourraient avoir manqué des patients répondant aux critères fondés sur la production d’urine. Notre définition de l’IRA fondée sur le taux de créatinine le plus élevée et le plus faible pendant l’admission pourrait également avoir conduit à un surdiagnostic. En outre, sans les résultats de laboratoires externes, il est possible que nous n’ayons pas saisi la mesure initiale réelle de la créatinine chez certains patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    肾衰竭患者的身体表现不佳,但是它的轨迹不太清楚。我们检查了肾脏疾病过程中的身体功能,包括过渡到透析。
    观察队列。
    在肾脏疾病(BRINK)队列研究中年龄≥45岁的社区居住成年人。
    估计的肾小球滤过率(eGFR)和尿白蛋白与肌酐之比(UACR)。
    使用短物理性能电池(SPPB)(主要)和步态速度(次要)来改变物理性能。
    线性混合效应回归模型。
    分析队列包括562名参与者,平均年龄为69.3岁(SD,9.8)年随访63个月。总的来说,49.8%是女性。此外,79.9%自我识别为白人,15.3%的人自称是黑人。总的来说,48.8%患有糖尿病。基线时的平均eGFR为48.1(SD,24.3)mL/min/1.73m2。在未经调整的分析中,较低的eGFR与SPPB评分下降幅度相关(P趋势<0.001).eGFR较低的参与者SPPB评分下降幅度更大,eGFR≥60mL/min/1.73m2的参与者每年-0.15(95%CI,-0.23~-0.07)点的梯度为-0.56(95%CI,-0.84~-0.27),eGFR<15mL/min/1.73m2和-0.61(95%CI,-0.90~-0.33)。在协变量调整模型中,透析开始后,SPPB没有继续下降。在评估步态速度变化的二次分析中,开始透析后,步态速度持续下降.在未调整和调整模型中,较高的UACR还与SPPB评分和步态速度的更大下降相关。
    少数参与者开始透析。
    我们发现慢性肾脏疾病分期和蛋白尿与身体机能下降之间存在分级关联。在协变量调整模型中开始透析后,SPPB的下降没有加速,而步态速度持续下降。
    身体功能是慢性肾脏病(CKD)以患者为中心的重要结果,但是,随着肾脏疾病的进展或患者开始透析时,身体状况是否会发生变化尚不清楚。我们发现衡量身体表现的指标,比如力量和行走速度,随着肾脏疾病的恶化而恶化。然而,与尚未开始透析的CKD非常晚期的患者相比,在开始透析后,1项物理性能测试组合出现稳定(而不是恶化)。而步态速度继续恶化。这些信息可能有助于为了解CKD并考虑治疗方案的患者提供咨询。它也可能有助于指导研究干预措施,以改善CKD患者的身体功能。
    UNASSIGNED: Patients with kidney failure have poor physical performance, but its trajectory is less clear. We examined physical function over the course of kidney disease, including the transition to dialysis.
    UNASSIGNED: Observational cohort.
    UNASSIGNED: Community-dwelling adults aged ≥45 years in the Brain in Kidney Disease (BRINK) cohort study.
    UNASSIGNED: Estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR).
    UNASSIGNED: Change in physical performance using the Short Physical Performance Battery (SPPB) (primary) and gait speed (secondary).
    UNASSIGNED: Linear mixed effects regression models.
    UNASSIGNED: The analytical cohort included 562 participants with mean age of 69.3 (SD, 9.8) years followed for up to 63 months. In total, 49.8% were women. In addition, 79.9% self-identified as White, and 15.3% self-identified as Black. In total, 48.8% had diabetes. Mean eGFR at baseline was 48.1 (SD, 24.3) mL/min/1.73 m2. In unadjusted analysis, lower eGFR was associated with greater decline in SPPB score (P trend < 0.001). The decline in SPPB score was larger among participants with lower eGFR, with a gradient from -0.15 (95% CI, -0.23 to -0.07) points per year for participants with eGFR ≥60 mL/min/1.73 m2 to -0.56 (95% CI, -0.84 to -0.27) for participants with eGFR <15 mL/min/1.73 m2 and -0.61 (95% CI, -0.90 to -0.33) after dialysis initiation. In covariate-adjusted models, SPPB did not continue to decline after dialysis initiation. In secondary analyses evaluating change in gait speed, gait speed continued to decline after dialysis initiation. Higher UACR was also associated with a greater decline in SPPB score and gait speed in unadjusted and adjusted models.
    UNASSIGNED: Small number of participants started dialysis.
    UNASSIGNED: We found a graded association of chronic kidney disease stage and albuminuria with decline in physical performance. The decline in SPPB was not accelerated after dialysis initiation in covariate-adjusted models, whereas gait speed continued to decline.
    Physical function is an important patient-centered outcome in chronic kidney disease (CKD), but whether physical performance changes as kidney disease progresses or when patients start dialysis is not well understood. We found that measures of physical performance, like strength and walking speed, worsened as kidney disease worsened. However, 1 combination of physical performance tests appeared stable (rather than getting worse) after starting dialysis compared to those with very advanced CKD who had not yet started dialysis, while gait speed continued to get worse. This information may help counsel patients who are learning about CKD and considering treatment options. It may also help guide research on interventions to improve physical function in patients with CKD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    凝血障碍在慢性肾脏病中起关键作用,血浆D-二聚体水平的形成或升高反映了凝血系统的激活。然而,其与IgA肾病(IgAN)肾脏疾病的严重程度和进展的关系尚不清楚。
    我们评估了2002年至2019年在第一附属医院诊断的1818例IgAN患者,浙江大学医学院.在肾活检时测量血浆D-二聚体水平。血浆D-二聚体水平与肾脏疾病进展事件之间的关系,定义为eGFR和终末期肾病(ESKD)下降50%,使用受限三次样条和Cox比例风险模型进行了测试。
    血浆D-二聚体水平中位数为220(170-388.5)µg/LFEU,显着高于健康对照组170(170-202)µg/LFEU。血浆D-二聚体水平与蛋白尿(r=0.211,p<0.001)、血清半乳糖缺乏IgA1(r=0.226,p=0.004)呈正相关,与eGFR(r=-0.127,p<0.001)、OxfordT(p<0.001)、C(p=0.004)评分呈负相关。在中位随访25.67(13.03-47.44)个月后,126例(6.93%)患者出现复合肾脏疾病进展事件。较高的血浆D-二聚体水平与肾脏疾病进展事件的风险增加相关(风险比,1.73;95%置信区间[95%CI],1.40-2.23)/ln-转化血浆D-二聚体(p<0.001),在性别调整后,年龄,蛋白尿,平均动脉压(MAP)和牛津分类评分。关于血浆D-二聚体的第一个三分位数,第二三分位数的风险比为1.48(95%CI,0.76-2.88),第三三分位数为3.03(95%CI,1.58-5.82)。
    高血浆D-二聚体水平与IgA肾病肾病严重程度的进展相关。
    UNASSIGNED: Coagulation disorders play a key role in chronic kidney disease, and the formation or elevation of plasma D-dimer levels reflects activation of the coagulation system. However, its relationship with the severity and progression of kidney disease in IgA nephropathy (IgAN) remains unclear.
    UNASSIGNED: We assessed 1818 patients with IgAN diagnosed between 2002 and 2019 at the First Affiliated Hospital, Zhejiang University School of Medicine. Plasma D-dimer levels were measured at the time of the renal biopsy. The association between plasma D-dimer levels and kidney disease progression events, defined as a 50% decline in eGFR and end-stage kidney disease (ESKD), was tested using restricted cubic splines and Cox proportional hazard models.
    UNASSIGNED: The median plasma D-dimer level was 220 (170-388.5) µg/L FEU, which was significantly higher than healthy controls 170 (170-202) µg/L FEU. Plasma D-dimer levels were positively correlated with proteinuria (r = 0.211, p < 0.001) and serum galactose-deficient IgA1 (r = 0.226, p = 0.004) and negatively correlated with eGFR (r=-0.127, p < 0.001) and Oxford T (p < 0.001) and C (p = 0.004) scores. After a median follow-up of 25.67 (13.03-47.44) months, 126 (6.93%) patients experienced composite kidney disease progression events. Higher plasma D-dimer levels were associated with an increased risk of kidney disease progression events (hazard ratio, 1.73; 95% confidence interval [95% CI], 1.40-2.23) per ln-transformed plasma D-dimer (p < 0.001), after adjustment for sex, age, proteinuria, Mean arterial pressure (MAP) and Oxford classification scores. In reference to the first tertile of plasma D-dimer, hazard ratios were 1.48 (95% CI, 0.76-2.88) for the second tertile, 3.03 (95% CI, 1.58-5.82) for the third tertile.
    UNASSIGNED: High plasma D-dimer levels were associated with the progression of kidney disease severity in IgA nephropathy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    慢性肾脏病(CDK)进展研究越来越多地使用基于估计的肾小球滤过率的替代终点。这些终点的临床特征为比较患者群体带来了新的挑战,因为传统的Cox模型可能会导致有偏差的估计,主要是因为它们没有假设风险函数。
    本研究基于案例研究,提出了在肾病学中使用具有三个最常用终点的参数生存分析模型。估计肾小球滤过率(eGFR)衰减>5毫升/年,eGFR下降>30%,并评估CKD分期的变化。
    病例研究是一项为期5年的回顾性队列研究,纳入了778名处于透析前阶段的患者。指数,威布尔,Gompertz,对数正态,和逻辑模型进行了比较,并对比例风险和加速失效时间(AFT)模型进行评估。
    端点具有完全不同的危险函数,证明为每个选择合适的模型的重要性。AFT模型更适用于协变量对这些终点的影响的临床解释。
    替代端点随着时间的推移具有不同的危险分布,这已经被肾脏病学家认可了。在肾脏病学研究中,应鼓励和推广在决策中捕获这些相关临床特征的更灵活的分析技术。
    UNASSIGNED: Chronic kidney disease (CDK) progression studies increasingly use surrogate endpoints based on the estimated glomerular filtration rate. The clinical characteristics of these endpoints bring new challenges in comparing groups of patients, as traditional Cox models may lead to biased estimates mainly because they do not assume a hazard function.
    UNASSIGNED: This study proposes the use of parametric survival analysis models with the three most commonly used endpoints in nephrology based on a case study. Estimated glomerular filtration rate (eGFR) decay > 5 mL/year, eGFR decline > 30%, and change in CKD stage were evaluated.
    UNASSIGNED: The case study is a 5-year retrospective cohort study that enrolled 778 patients in the predialysis stage. Exponential, Weibull, Gompertz, lognormal, and logistic models were compared, and proportional hazard and accelerated failure time (AFT) models were evaluated.
    UNASSIGNED: The endpoints had quite different hazard functions, demonstrating the importance of choosing appropriate models for each. AFT models were more suitable for the clinical interpretation of the effects of covariates on these endpoints.
    UNASSIGNED: Surrogate endpoints have different hazard distributions over time, which is already recognized by nephrologists. More flexible analysis techniques that capture these relevant clinical characteristics in decision-making should be encouraged and disseminated in nephrology research.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    我们的目标是评估潜在的社会人口统计学,临床,和生活方式相关的肾功能下降的危险因素(KFD),定义为估计肾小球滤过率(eGFR)下降≥30%,在伊朗队列研究中。
    7190名年龄在20-90岁之间的参与者(4049名女性),其中2-5个eGFR数据来自检查(2001-2005年至2015-2018年)。Cox比例风险模型用于检查潜在危险因素与eGFR下降之间的关联。
    在11.5年的随访中,1471(889名女性)参与者发生了KFD事件,粗发生率为每10,000人年192.1(182.6-202.2)。在总人口中,年龄较大,女性性别,高血压前期,高血压,糖尿病,丧偶/离婚的州,高甘油三酯(TG),心血管疾病(CVD),较高的基线eGFR与较高的eGFR显着相关,而适度的体力活动和糖尿病家族史与较低的KFD风险相关(所有p值<.05)。心血管疾病流行于女性,但不是男性,糖尿病,且绝经后妇女高血压比绝经前妇女是KFD的显著危险因素。根据基线时慢性肾病(CKD)的存在,较高的eGFR降低了CKD患者的KFD风险,而非CKD患者的KFD风险增加(所有p表示交互作用<.05).
    KFD与受性别影响的伊朗城市人口中多个可改变的风险因素有关,更年期状态,和初始肾功能。针对这些因素的干预措施可能有助于减轻KFD的负担。关键信息:更年期状态可能影响心脏代谢危险因素与KFD之间的关系;较高的基线eGFR对KFD风险的影响在肾功能保留的受试者和CKD患者之间存在差异。性别之间的相互作用,更年期状态,在KFD上具有不同危险因素的基线肾功能可能有助于进行肾脏风险预测评分,以识别普通人群中可能从早期预防中受益的风险人群。
    We aimed to assess the potential socio-demographic, clinical, and lifestyle-related risk factors for kidney function decline (KFD), defined as ≥30% estimated glomerular filtration rate (eGFR) decline, in an Iranian cohort study.
    7190 participants (4049 women) aged 20-90 years with 2-5 eGFR data from examinations (2001-2005 to 2015-2018) were included. Cox proportional hazard models were used to examine the association between potential risk factors and eGFR decline.
    During 11.5 years of follow-up, 1471 (889 women) participants had incident KFD with a crude incidence rate of 192.1 (182.6-202.2) per 10,000 person-year. Among the total population, older age, female gender, prehypertension, hypertension, diabetes, widowed/divorced states, higher triglycerides (TG), prevalent cardiovascular diseases (CVD), and higher baseline eGFR were significantly associated with higher, while moderate physical activity and a positive family history of diabetes were associated with lower risk of KFD (all p values <.05). Prevalent CVD in women but not men, diabetes, and hypertension among postmenopausal than premenopausal women were significant risk factors of KFD. According to the presence of chronic kidney disease (CKD) at baseline, higher eGFR decreased the risk of KFD in patients with CKD and increased KFD risk in those without CKD (all p for interactions <.05).
    KFD is associated with multiple modifiable risk factors among the Iranian urban population that is affected by gender, menopausal status, and initial kidney function. Interventions targeting these factors might potentially help reduce the burden of KFD.Key messages:Menopausal status may influence the relationship between cardiometabolic risk factors and KFD;The impact of higher baseline eGFR on the risk of KFD differed between subjects with preserved kidney function and CKD patients.The interaction between gender, menopausal status, and baseline kidney function with different risk factors on KFD may help to make renal risk prediction scores to identify those in the general population at risk who may benefit from early prevention.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    未经评估:血压(BP)的访视变异性(VVV)是中风和冠心病的重要危险因素,也可能与肾脏损害和慢性肾脏疾病(CKD)的发展有关。关于BP中VVV与免疫球蛋白A肾病(IgAN)患者CKD进展风险之间的相关性的数据有限。我们旨在评估BP中VVV与IgAN进展的关系。
    UNASSIGNED:我们评估了北京大学第一医院的1376例IgAN患者。BP中的主要VVV表示为标准偏差(SD),变异系数(CV)和平均实际变异性(ARV)。血压变异性与复合肾脏疾病进展事件的相关性,定义为估计的肾小球滤过率(eGFR)和肾衰竭下降50%,使用Cox模型进行检查。
    UNASSIGNED:在44.1个月的中位随访期间(四分位距23.0-76.7),247例(18.0%)患者出现复合肾脏疾病进展事件。收缩压血压(SBP)的SD值越高,肾脏疾病进展事件的风险增加{风险比[HR]1.07[95%置信区间(CI)1.03-1.11];最大校正后P<.001},包括基线SBP和前12个月期间的平均SBP。使用SDSBP值的第一个四分位数作为参考,SDSBP值较高的患者发生复合肾脏疾病进展事件的风险较高;最高四分位数的HR为2.12(95%CI1.31~3.44)(趋势P<.001).在分析舒张压血压的SD时可以观察到类似的趋势,但风险并未显著增加.当用CV和ARV分析时,这些关联是相似的。
    未经证实:SBP变异性与IgAN肾病进展显著相关。
    UNASSIGNED: The visit-to-visit variability (VVV) in blood pressure (BP) is an important risk factor for stroke and coronary heart disease and may also be associated with kidney damage and the development of chronic kidney disease (CKD). Data on the association between VVV in BP and the risk of CKD progression among patients with immunoglobulin A nephropathy (IgAN) are limited. We aimed to evaluate the relationships of VVV in BP with the progression of IgAN.
    UNASSIGNED: We assessed 1376 patients with IgAN at Peking University First Hospital. The main VVV in BP was expressed as the standard deviation (SD), coefficient of variation (CV) and average real variability (ARV). The associations of variability in BP with composite kidney disease progression events, defined as a 50% decline in estimated glomerular filtration rate (eGFR) and kidney failure, were examined using Cox models.
    UNASSIGNED: During a median follow-up of 44.1 months (interquartile range 23.0-76.7), 247 (18.0%) patients experienced composite kidney disease progression events. With a higher SD in systolic BP (SBP) values, the risk of kidney disease progression events increased {hazard ratio [HR] 1.07 [95% confidence interval (CI) 1.03-1.11]; P < .001} after maximal adjustment, including baseline SBP and mean SBP during the first 12-month period. Using the first quartile of SD SBP values as the reference, the risk of composite kidney disease progression events was higher among patients with higher SD SBP values; the HR was 2.12 (95% CI 1.31-3.44) in the highest quartile (P for trend < .001). A similar trend could be observed when analysing the SD of diastolic BP, but the risk was not significantly increased. The associations were similar when analysed with the CV and ARV.
    UNASSIGNED: SBP variability was significantly associated with kidney disease progression in IgAN.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:血浆可溶性肿瘤坏死因子受体1(sTNFR1)和sTNFR2在有或没有急性肾损伤(AKI)住院后临床事件预后中的作用尚不清楚。
    方法:前瞻性队列。
    方法:来自ASSESS-AKI的医院幸存者(评估,串行评估,以及随后的急性肾损伤后遗症)和ARID(Derby中的AKI风险)研究,在住院期间是否有AKI,他们有基线血清样本进行生物标志物测量。
    方法:我们从放电后3个月获得的血浆样品中测量了sTNFR1和sTNFR2。
    结果:生物标志物与纵向肾脏疾病发病率和进展的关系,心力衰竭,并对死亡进行了评估。
    方法:Cox比例风险模型。
    结果:在1,474名进行血浆生物标志物测量的参与者中,19%有肾脏疾病进展,14%的人后来出现心力衰竭,21%在4.4年的中位随访期间死亡.对于肾脏的结果,sTNFR1和sTNFR2每倍增一次的校正HR(AHRs)分别为2.9(95%CI,2.2-3.9)和1.9(95%CI,1.5-2.5).住院期间的AKI并未改变生物标志物与肾脏事件之间的关联。对于心力衰竭,sTNFR1和sTNFR2的每倍增浓度的AHR分别为1.9(95%CI,1.4-2.5)和1.5(95%CI,1.2-2.0).对于死亡率,sTNFR1的AHR为3.3(95%CI,2.5-4.3),sTNFR2为2.5(95%CI,2.0-3.1)。就生物标志物与结果之间的关联程度而言,ARID的发现在质量上相似。
    结论:不同的生物标志物平台和AKI定义;对其他种族群体的普适性有限。
    结论:出院后3个月测量的血浆sTNFR1和sTNFR2与指示入院期间的AKI状况无关,与临床事件独立相关。sTNFR1和sTNFR2可能有助于随访期间患者的风险分层。
    The role of plasma soluble tumor necrosis factor receptor 1 (sTNFR1) and sTNFR2 in the prognosis of clinical events after hospitalization with or without acute kidney injury (AKI) is unknown.
    Prospective cohort.
    Hospital survivors from the ASSESS-AKI (Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury) and ARID (AKI Risk in Derby) studies with and without AKI during the index hospitalization who had baseline serum samples for biomarker measurements.
    We measured sTNFR1 and sTNFR2 from plasma samples obtained 3 months after discharge.
    The associations of biomarkers with longitudinal kidney disease incidence and progression, heart failure, and death were evaluated.
    Cox proportional hazard models.
    Among 1,474 participants with plasma biomarker measurements, 19% had kidney disease progression, 14% had later heart failure, and 21% died during a median follow-up of 4.4 years. For the kidney outcome, the adjusted HRs (AHRs) per doubling in concentration were 2.9 (95% CI, 2.2-3.9) for sTNFR1 and 1.9 (95% CI, 1.5-2.5) for sTNFR2. AKI during the index hospitalization did not modify the association between biomarkers and kidney events. For heart failure, the AHRs per doubling in concentration were 1.9 (95% CI, 1.4-2.5) for sTNFR1 and 1.5 (95% CI, 1.2-2.0) for sTNFR2. For mortality, the AHRs were 3.3 (95% CI, 2.5-4.3) for sTNFR1 and 2.5 (95% CI, 2.0-3.1) for sTNFR2. The findings in ARID were qualitatively similar in terms of the magnitude of association between biomarkers and outcomes.
    Different biomarker platforms and AKI definitions; limited generalizability to other ethnic groups.
    Plasma sTNFR1 and sTNFR2 measured 3 months after hospital discharge were independently associated with clinical events regardless of AKI status during the index admission. sTNFR1 and sTNFR2 may assist with the risk stratification of patients during follow-up.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    高同型半胱氨酸血症(HHcy)在慢性肾脏病(CKD)患者中非常常见,与这些患者的心血管事件风险和死亡率相关。然而,HHcy在CKD主要病因中的患病率及其在肾脏疾病进展中的作用尚不清楚.在这项研究中,我们调查了221例IgA肾病(IgAN)患者和194例其他原发性肾小球疾病患者不同CKD分期中HHcy的患病率。我们还评估了同型半胱氨酸(Hcy)[在校正估计的肾小球滤过率(eGFR)后]与CKD进展事件的相关性,定义为ESKD或eGFR下降50%,在365名IgAN患者的队列中。HHcy患病率为67.9%(150/221),53.5%(76/142),51.5%(17/33),IgAN患者占42.1%(8/19),膜性肾病,微小变化疾病,局灶性节段肾小球硬化,分别。Hcy/eGFR比值与IgAN的病理特征显著相关,包括全球肾小球硬化的比例(r=0.38,p<0.001),缺血起源的肾小球硬化的比例(r=0.32,p<0.001),和肾小管萎缩/间质纤维化的严重程度(r=0.57,p<0.001)。重要的是,Hcy/eGFR比值是CKD进展事件的独立危险因素(风险比,1.38;95%置信区间,1.13-1.68;p=0.002)。CKD进展事件的风险随Hcy/eGFR比值的增加而增加,但当Hcy/eGFR比值>1.79时达到平台期。我们的发现表明,Hcy/eGFR比值升高可能是IgAN肾脏预后不良的早期标志。
    Hyperhomocysteinemia (HHcy) is very common among patients with chronic kidney disease (CKD), and related to the risk of cardiovascular events and mortality in these patients. However, the prevalence of HHcy in primary causes of CKD and its role in kidney disease progression are not well-understood. In this study, we investigated the prevalence of HHcy in different CKD stages in 221 patients with IgA nephropathy (IgAN) and 194 patients with other primary glomerular diseases. We also evaluated the association of homocysteine (Hcy) [after adjusted for estimated glomerular filtration rate (eGFR)] with CKD progression event, defined as ESKD or 50% decline in eGFR, in a cohort of 365 patients with IgAN. The prevalence of HHcy was 67.9% (150/221), 53.5% (76/142), 51.5% (17/33), and 42.1% (8/19) in patients with IgAN, membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, respectively. The Hcy/eGFR ratio was significantly associated with pathologic features of IgAN, including the proportion of global glomerulosclerosis (r = 0.38, p < 0.001), the proportion of ischemia originated glomerular sclerosis (r = 0.32, p < 0.001), and the severity of tubular atrophy/interstitial fibrosis (r = 0.57, p < 0.001). Importantly, Hcy/eGFR ratio was an independent risk factor for CKD progression event (hazard ratio, 1.38; 95% confidence interval, 1.13-1.68; p = 0.002). The risk of CKD progression events continuously increased with the Hcy/eGFR ratio, but reached a plateau when Hcy/eGFR ratio was >1.79. Our findings suggest that elevated Hcy/eGFR ratio may be an early marker of poor renal outcome in IgAN.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    未经证实:蛋白尿是IgA肾病肾脏结局的重要危险因素。随机尿蛋白与肌酐比值(PCR),随机白蛋白与肌酐比值(ACR),和24小时尿蛋白排泄(24小时UP)已广泛应用于临床实践。然而,长期肾脏结局的最佳预测指标仍存在争议.本研究旨在比较IgA肾病的三种测量结果。
    UNASSIGNED:我们对766例IgA肾病患者进行了回顾性研究。基线ACR之间的关联,PCR,和24小时UP与慢性肾脏病(CKD)进展事件,定义为50%估计肾小球滤过率(eGFR)下降或终末期肾病(ESKD),进行了测试和比较。
    未经批准:在这项研究中,ACR,PCR,与24hUP呈高度相关(r=0.671~0.847,P<0.001)。在中位随访29.88(14.65-51.65)个月后,51例(6.66%)患者达到CKD进展事件。在单变量分析中,ACR在预测IgA肾病的预后方面表现更好,与PCR和24小时UP相比,受试者工作曲线(ROC)曲线下面积更高。在对传统风险因素进行调整后,ACR与复合CKD进展事件最相关[每对数转化ACR,风险比(HR):2.82;95%(95%CI):1.31-6.08;P=0.008]。
    未经证实:在IgA肾病中,ACR,PCR,和24小时UP有很高的相关性。ACR在预测IgA肾病的预后方面表现更好。
    UNASSIGNED: Proteinuria is a strong risk factor for renal outcomes in IgA nephropathy. Random urine protein-to-creatinine ratio (PCR), random albumin-to-creatinine ratio (ACR), and 24-h urine protein excretion (24-h UP) have been widely used in clinical practice. However, the measurement which is the best predictor of long-term renal outcomes remains controversial. This study aimed to compare the three measurements in IgA nephropathy.
    UNASSIGNED: We conducted a retrospective study of 766 patients with IgA nephropathy. The associations among baseline ACR, PCR, and 24-h UP with chronic kidney disease (CKD) progression event, defined as 50% estimated glomerular filtration rate (eGFR) decline or end stage kidney disease (ESKD), were tested and compared.
    UNASSIGNED: In this study, ACR, PCR, and 24-h UP showed high correlation (r = 0.671-0.847, P < 0.001). After a median follow-up of 29.88 (14.65-51.65) months, 51 (6.66%) patients reached the CKD progression event. In univariate analysis, ACR performed better in predicting the prognosis of IgA nephropathy, with a higher area under the receiver operating curve (ROC) curve than PCR and 24-h UP. After adjustment for traditional risk factors, ACR was most associated with composite CKD progression event [per log-transformed ACR, hazard ratio (HR): 2.82; 95% (95% CI): 1.31-6.08; P = 0.008].
    UNASSIGNED: In IgA nephropathy, ACR, PCR, and 24-h UP had a high correlation. ACR performed better in predicting the prognosis of IgA nephropathy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号